Zepbound vs. Ozempic

"GLP-1 drug" gets used as a catch-all in headlines and casual conversation, and it obscures a real structural difference between the two most-searched names in the category. Semaglutide, the active ingredient in Ozempic and Wegovy, is a GLP-1 receptor agonist: it mimics glucagon-like peptide-1, a gut hormone that slows stomach emptying, increases insulin release when blood sugar is high, and signals satiety to the brain. Tirzepatide, the active ingredient in Zepbound and Mounjaro, does that too, but it also activates GIP (glucose-dependent insulinotropic polypeptide) receptors at the same time — a second gut hormone pathway that semaglutide doesn't touch. That dual mechanism is the entire reason tirzepatide is described as a "dual agonist" while semaglutide is described as a "GLP-1 agonist," and it's the mechanistic basis researchers point to when explaining why tirzepatide's trial results tend to show larger average effects.

The two molecules also come from competing companies with fully separate development programs, manufacturing supply chains, and patent timelines — there's no shared formulation or shared trial data between them, despite how often they're name-checked together. Eli Lilly develops and markets tirzepatide under two brand names depending on the approved use: Mounjaro for type 2 diabetes, Zepbound for weight management and sleep apnea. Novo Nordisk does the same thing with semaglutide, splitting it into Ozempic for diabetes and cardiovascular risk reduction, and Wegovy for weight management, with a third oral version, Rybelsus, also approved for diabetes. Same active ingredient, different brand, different approved use, different maximum dose — a pattern that shows up again in the next section and explains most of the public confusion around these drugs.

Semaglutide has simply been on the market longer. Ozempic's original diabetes approval dates to December 2017, giving prescribers and researchers roughly five extra years of real-world exposure data compared with tirzepatide, whose first approval (as Mounjaro, for diabetes) came in May 2022, with Zepbound's weight-management approval following in November 2023 and the obstructive sleep apnea indication arriving in December 2024. That longer track record doesn't make semaglutide inherently safer or better studied for every outcome, but it does mean there's a deeper pool of longer-term, real-world safety data specifically for semaglutide simply because more people have been on it for more years.

This is the single most common source of confusion in any "Zepbound vs. Ozempic" search, so it's worth stating plainly: Ozempic is not FDA-approved for weight loss. Its label covers glycemic control in adults with type 2 diabetes, plus a cardiovascular risk-reduction indication for adults with type 2 diabetes and established heart disease, added after the SUSTAIN 6 outcomes trial, and more recently a chronic kidney disease risk-reduction indication for adults with type 2 diabetes and CKD. Weight loss is a well-documented side effect of semaglutide, and some prescribers do write Ozempic off-label for that purpose, but the drug's actual approved indication — and the dosing schedule, insurance coding, and clinical trial evidence tied to that approval — is diabetes, not obesity.

Wegovy is the semaglutide brand that carries the weight-management approval. It's the same active ingredient as Ozempic, made by the same company, delivered through a similar once-weekly pen, but it's a separate FDA approval with its own dosing schedule that tops out at 2.4 mg weekly, compared with Ozempic's 2 mg ceiling. If your actual goal is comparing weight-loss-approved products head to head, the more precise comparison is Zepbound vs. Wegovy — but because "Ozempic" became the household name for semaglutide broadly during its early media coverage, most people search and talk about "Zepbound vs. Ozempic" even when they mean the weight-management comparison. This article addresses both: what Ozempic itself is actually approved and studied for, and where Wegovy fits into the weight-loss comparison people usually intend.

The same brand-splitting happens on the tirzepatide side. Mounjaro carries the original type 2 diabetes approval; Zepbound is the identical molecule, tirzepatide, approved separately for chronic weight management and, since December 2024, for moderate-to-severe obstructive sleep apnea in adults with obesity — the first drug ever approved specifically for that sleep apnea indication. So a fully accurate, indication-matched comparison actually runs four ways: Mounjaro vs. Ozempic for diabetes, and Zepbound vs. Wegovy for weight management, with Zepbound carrying the added OSA approval that none of the other three brands have.

None of this means a doctor can't prescribe Ozempic for weight-related reasons, or Zepbound off-label for something outside its label — prescribers have latitude to prescribe off-label when they judge it clinically appropriate. It does mean that insurance plans, formulary rules, and prior-authorization requirements are generally built around the approved indication on the label, which is part of why coverage for weight-loss use of a diabetes-labeled drug can get complicated, a point covered further in the cost section below.

The first four rows above come from two entirely separate trial programs, run at different times, in different countries, with different research teams — SURMOUNT-1 for tirzepatide and STEP 1 for semaglutide (dosed at Wegovy's 2.4 mg weight-management level). Both enrolled adults with obesity or overweight who did not have diabetes, and both ran for a similar duration — 72 weeks versus 68 weeks — which makes them reasonably comparable in design, but they are not the same study. Participants weren't randomly split between the two drugs; they were two different groups of people, in two different trials, each compared only against their own trial's placebo arm. Treat any side-by-side percentage from these four rows as an indirect, cross-trial comparison — informative, but not the same evidentiary weight as a randomized head-to-head.

A true head-to-head trial does exist, and it's the last two rows: SURMOUNT-5, a Lilly-sponsored trial that directly randomized 751 adults with obesity to either tirzepatide or semaglutide at each drug's maximum tolerated weight-management dose, then followed them for 72 weeks at the same 32 sites under the same protocol. That trial found tirzepatide produced greater average weight loss — about 20.2% versus about 13.7% — along with a larger share of participants reaching 25% or greater weight loss. But the semaglutide arm in SURMOUNT-5 was dosed at 1.7 mg and 2.4 mg, which is Wegovy's dosing range, not Ozempic's. Ozempic itself, dosed and labeled for diabetes and capped at 2 mg, was not the product studied in that trial, because comparing a diabetes-dosed product against a weight-management-dosed product for weight-loss outcomes wouldn't answer a clinically meaningful question. So the accurate statement is: there is a real head-to-head trial between tirzepatide and semaglutide for weight loss, but it compared Zepbound to Wegovy, not to Ozempic specifically.

Individual results vary widely around every one of these averages — some people lose far more than the mean, some lose far less, and response depends on dose reached, how long someone stays on treatment, diet and activity changes made alongside the medication, and individual metabolic factors that trials can't fully control for. A trial average is a population-level statistic, not a prediction for any one person's outcome, on either drug.

Both drugs share the same weekly rhythm and the same general titration philosophy — start low, hold each dose for roughly a month, step up gradually to reduce gastrointestinal side effects, and land on whatever maintenance dose the patient tolerates well and responds to. That similarity in structure is real and makes both drugs fit the same kind of weekly reminder habit.

What isn't comparable is the raw milligram number. Because tirzepatide and semaglutide are different molecules with different potency and different receptor binding, a 2.5 mg starting dose of tirzepatide is not "weaker" than a 0.25 mg starting dose of semaglutide just because the number is larger — the two scales aren't measuring the same thing, the way a milligram of one blood pressure drug isn't equivalent to a milligram of a completely different one. Zepbound's dosing ladder runs 2.5, 5, 7.5, 10, 12.5, and 15 mg. Ozempic's runs 0.25 mg (a titration-only starting dose, not intended for glycemic effect), 0.5, 1, and 2 mg. Wegovy, semaglutide's weight-management version, extends one step further to 1.7 and 2.4 mg. Comparing "Zepbound is dosed up to 15 while Ozempic tops out at 2" as evidence that one is stronger is a common but mistaken shortcut — it says nothing meaningful without accounting for the different potency per milligram of each molecule.

The four-week step-up interval on both drugs exists for the same reason: giving the gut time to adjust reduces the odds of severe nausea or vomiting derailing treatment early. Skipping ahead in the titration schedule, on either drug, is generally discouraged by prescribers for exactly that reason — the schedule is there to manage tolerability, not as an arbitrary bureaucratic pace.

Because tirzepatide and semaglutide both slow gastric emptying and act on overlapping gut-hormone pathways, their side-effect profiles look more similar than different, and that similarity is the more clinically relevant story than any headline difference. Both drugs' prescribing information lists nausea, diarrhea, vomiting, and constipation as the most common adverse effects, most pronounced during the first weeks after starting or after each dose increase, and generally easing as the body adjusts to a given dose. Reduced appetite, which is part of the intended effect for weight management, gets listed as a side effect on both labels as well, alongside less common effects like abdominal pain, indigestion, and injection-site reactions.

Both drugs also carry the identical boxed warning — the FDA's most serious label warning category — for the risk of thyroid C-cell tumors, including medullary thyroid carcinoma, based on findings in rodent studies where both tirzepatide and semaglutide caused dose-dependent thyroid C-cell tumors at clinically relevant exposures. Whether this risk translates to humans hasn't been established either way for either drug, since the relevance of the rodent findings to human physiology remains unresolved in the scientific literature. Both Zepbound's and Ozempic's labels contraindicate use in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and both instruct prescribers to counsel patients on symptoms worth reporting, such as a neck mass, persistent hoarseness, difficulty swallowing, or shortness of breath.

Where the two diverge somewhat is in indirect comparisons of GI tolerability at maximum doses — SURMOUNT-5, the head-to-head trial referenced above, reported broadly consistent safety profiles between the two arms, with gastrointestinal events as the most common adverse effect on both sides and no dramatic difference in discontinuation rates attributable to side effects. In practice, which drug an individual tolerates better is difficult to predict in advance and varies person to person; some people who struggle with nausea on one drug find the other more tolerable, and vice versa, without a clear pattern that applies universally.

Neither drug is reliably cheap without help, and the coverage hurdles both face follow a similar pattern rather than a sharply different one. Ozempic, prescribed for its approved diabetes indication, tends to clear insurance formularies more easily simply because type 2 diabetes is a well-established, widely covered diagnosis with decades of payer precedent behind it. Zepbound, approved for weight management, runs into the same category-level exclusions that many employer health plans apply to anti-obesity medications broadly — a plan-design decision that often has nothing to do with which specific weight-management drug is prescribed, and everything to do with whether the plan covers that drug class at all.

Both manufacturers run their own manufacturer savings card programs with list-price and eligibility rules that shift year to year, and both companies operate a direct-to-consumer self-pay channel — Lilly's LillyDirect and Novo Nordisk's NovoCare pharmacy — for patients without coverage. The general shape of the cost problem is the same on both sides: a covered diagnosis with a favorable formulary placement usually means a manageable copay, while an excluded use or an uncovered plan usually means facing something closer to list price, discounted only by whichever savings program applies. This site covers the specific current dollar figures for Zepbound pricing and savings-card terms in a dedicated cost guide, linked below, rather than repeating them here.